The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts
Portfolio Pulse from Benzinga Insights
IDEAYA Biosciences (NASDAQ:IDYA) has received mixed analyst ratings over the last quarter, with 3 bullish and 5 somewhat bullish ratings. The average 12-month price target for IDYA is $44.5, with a high of $53.00 and a low of $36.00, representing a 16.49% increase from the previous average of $38.20. Analysts from firms including Goldman Sachs, RBC Capital, JP Morgan, Wedbush, and Guggenheim have updated their ratings and price targets. IDEAYA Biosciences is an oncology-focused precision medicine company with a negative revenue trend of -72.94% over 3 months and a high net margin of -341.38%. The company has a strong ROE of -5.44% and ROA of -5.17%, with no debt (debt-to-equity ratio of 0.0).
January 26, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEAYA Biosciences has a mixed outlook from analysts, with an updated average price target of $44.5, indicating potential growth. The company's financials show a significant revenue decline but strong profitability metrics and no debt.
The updated average price target suggests analysts believe in the potential growth of IDYA, despite recent revenue declines. The strong ROE and ROA, along with the absence of debt, may mitigate concerns about the company's financial health. The mixed analyst ratings indicate that while there is optimism, there is also caution, which could lead to a moderate positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100